- CDRO and CDMO integration to drive full-cycle pharmaceutical development collaboration

 ▲    BXPLANT CEO Min-geun Jo and PCMO Director Min Cho at the MoU Signing

PCMO (Director Min Cho, hereafter referred to as the Center) announced that it has signed a Memorandum of Understanding (MoU) with BXPLANT (CEO Min-geun Jo, Hee-seon Kim) on December 3rd, aiming for comprehensive collaboration in the full cycle of pharmaceutical development.

The main objective of this MoU is for the two organizations to share the latest trends in the pharmaceutical CDRO (Contract Development and Research Organization) and CDMO (Contract Development and Manufacturing Organization) industries, and to establish a collaborative network throughout the entire pharmaceutical development process. BXPLANT plans to combine its CDRO services with PCMO's manufacturing technologies and production capabilities to enhance the domestic bio industry and secure competitiveness in the global bio market.

BXPLANT provides CDRO services to domestic biotech venture companies, offering full-cycle support from clinical development strategy formulation to preclinical and clinical phases. The company also plans to expand its role as a "scalerator," focusing on company discovery, investment attraction, and consulting for capital raising, thus actively supporting the growth of biotech companies.

PCMO plans to complete the construction of mRNA vaccine production facility by the first half of 2025, and based on its accumulated experience from over 100 projects, it will further strengthen support for domestic pharmaceutical and bio companies. Since its establishment in 2017, with investments from Ministry of Trade, Industry and Energy and Jeonnam-do Hwasun County, PCMO has been continuously supporting the development of domestic vaccines and biopharmaceuticals.

 ▲    Logos of BXPLANT and PCMO

Through this collaboration, the two organizations aim to build a full-cycle collaboration network based on their respective expertise, expanding technological innovation and growth potential in the bio sector. As global biotech companies have been actively investing in the CDRO and CDMO markets in recent years, the future developments of the two organizations are expected to be highly promising.

Meanwhile, BXPLANT CEO Min-geun Jo emphasized, "Through our collaboration with PCMO, we aim to combine our CDRO services with manufacturing and production capabilities, elevating the level of the domestic bio industry and strengthening our competitiveness in the global market. This MoU is not just a business agreement but an important starting point that will help accelerate the growth of the biotech ecosystem."